Best Skin Research LLC

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder	Recruiting	Phase 2	2026-10-06	NCT07223697
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder	Active, not recruiting	Phase 2	2026-08-10	NCT06863961
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense	Acneiform Eruptions, Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, acne, bacterial infectious disease, dermatitis, hidradenitis, hidradenitis suppurativa, sebaceous gland disorder, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder	Active, not recruiting	Phase 2	2026-06-30	NCT06993610

Clinical trials